BeyondSpring

Traded on the St. Petersburg Stock Exchange

BeyondSpring is a clinical stage biopharmaceutical company, that focuses on the development and commercialization of immuno-oncology cancer therapies. It was founded in 2010 and is headquartered in New York.

P/E

Net profit

P/B

Book value

Debts

Net debt

Yield

Growth potential

Report period	2018	2019	2020	2021	2022	Q2 23
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Report period	2017	2018	2019	2020	2021	2022
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Report period	2018	2019	2020	2021	2022	Q2 23 TTM
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Report period	2018	2019	2020	2021	2022	Q2 23 TTM
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin

Ticker	Name	Type	Nominal value	ISIN	Price
BYSI:US	BeyondSpring	Common share	-	KYG108301006	$3.12

BeyondSpring news

14.04.2022

BeyondSpring's GAAP loss for 2021 was $68.208 million, up 6.9% from $63.821 million in the previous year. Revenue increased 7.5 times to $1.351 million from $0.18 million a year earlier.

Source:

beyondspringpharma.com

All BeyondSpring news

General information

Company name	BeyondSpring
Tags	#biotechnology, #pharmacy, #cancer treatment
Sector	Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology
Business address	28 Liberty Street 39th Floor New York, NY 10005 United States
Mailing address	28 Liberty Street 39th Floor New York, NY 10005 United States
Website	beyondspringpharma.com

BeyondSpring

BeyondSpring balance sheet

BeyondSpring cash flows

BeyondSpring multipliers

BeyondSpring profitability

BeyondSpring dividend policy

BeyondSpring shares